Nippon Chemiphar Co., Ltd. (TYO:4539)

Market Cap	5.81B +10.0%
Revenue (ttm)	33.09B +1.6%
Net Income	198.00M -32.7%
EPS	54.79 -32.8%
Shares Out	3.61M
PE Ratio	29.40
Forward PE	n/a
Dividend	50.00 (3.10%)
Ex-Dividend Date	Mar 30, 2026

Volume	400
Open	1,603.00
Previous Close	1,630.00
Day's Range	1,603.00 - 1,611.00
52-Week Range	1,457.00 - 1,857.00
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About Nippon Chemiphar

Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1950
• Employees: 855
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4539

Financial Performance

In fiscal year 2026, Nippon Chemiphar's revenue was 33.09 billion, an increase of 1.60% compared to the previous year's 32.57 billion. Earnings were 198.00 million, a decrease of -32.65%.